This abstract from the American Society of Hematology Annual Meeting and Exposition (ASH 2021) presented interim results of the Phase 3 randomized SEQUOIA study which evaluated the efficacy and safety of zanubrutinib versus BR in previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients without the high-risk mutation,17p deletion
During ASH 2020, Dr. Paolo Ghia discussed the ASCEND Study – Acalabrutinib vs. Idelalisib + Rituximab or Bendamustine + Rituximab in Relapsed or Refractory CLL. Dr. Ghia presented the final analyses of the ASCEND trial after nearly two years of follow-up. Acalabrutinib was the clear winner.
The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr.
The phase III Alliance A041202 collaborative multi-centered trial demonstrated once and for all the superiority of ibrutinib versus Bendamustine/Rituximab (BR) when used frontline in older CLL patients. Dr. Brander from Duke fills in more details at iwCLL 2019 in Scotland.
This is huge. This is game changing. This was one of the six late-breaking abstracts from ASH (American Society of Hematology) 2018 Annual Meeting and Congress that were selected because they reflect the most important, latest research in hematology and change how we manage heme malignancies. Dr. Tait Shanafelt
By Brian Koffman, MD This is really big news. Practice changing news. Dr. Jennifer Woyach of Ohio State presented the results of the large phase III Alliance A041202 collaborative multi-centered trial that was designed to see if we should change how we treat chronic lymphocytic leukemia in older patients who